Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIH-MAB phase IIa infliximab induction study in treatment-naive autoimmune hepatitis
2017-003311-19Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in autoimmune hepatitis (AIH), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Biochemical remission of autoimmune hepatitis. Started Sep 2017; status: completed.
02
Drugs
infliximab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on 2017-003311-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003311-19.